On September 17th, OBIO held a dinner to bring together CAAP and CAAP Alumni companies. OBIO would like to thank everyone who came out and joined us to discuss common experiences, challenges and what's coming next.
On September 10th, OBIO organized a cross-border networking event in Boston at the Consulate General of Canada. The event was supported by the Consulate General and law firms Fasken and Choate. Over 45 investors, strategics, as well as executives from high potential Canadian health science companies packed the Canada Room at the Consulate and resulted in numerous investor-company interactions.
Ontario Genomics is pleased to announce that a new round of Genome Canada’s Genomic Applications Partnership Program (GAPP) is now open (Round 18). The program provides a unique opportunity for Receptor organizations to collaborate with an ’omics researcher, and to leverage their R&D investments with public funding.
Application deadline: October 28, 2019
Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce the sale of its surface modification business to Evonik, a German based specialty chemical company with revenues in excess of €13 billion in 2018.
This week, the Globe & Mail reported that venture-capital investment surged to its strongest first half on record, injecting $2.15-billion into Canadian startups and scale-ups, according to the Canadian Venture Capital & Private Equity Association (CVCA).
FedDev Ontario is investing up to $6.24 million for the Ontario Bioscience Innovation Organization (OBIO®) to boost investment, market access and mentorship opportunities for companies across southern Ontario looking to commercialize their medical innovations.
iMerciv was accepted into the Fall 2019 Cohort of the Canadian Technology Accelerator in Silicon Valley, which helps high-potential Canadian technology companies access the unique resources of Silicon Valley to grow at a global scale.
Profound Medical announced that they have received 510(k) clearance from the U.S. Food and Drug Administration to market TULSA-PRO® for ablation of prostate tissue.
On August 21st, OBIO hosted Norton Rose Fulbright’s Anthony de Fazekas (Partner, Head of Technology & Innovation) and Vanessa Grant (Partner), Lumira Ventures’ Jacki Jenuth (Partner), and University of Toronto’s Karen Temple (Commercialization Manager) who discussed practical considerations for licensing health science technologies from tech transfer offices, and how these agreements can impact a company’s future investability.
Able Innovations will be pitching live against 9 other companies for a chance to win up to $75,000 in cash prizes at the Lions Lair.
Perimeter Medical Imaging announce the completion of a pre-public financing round raising $C4.4million.
Hosted by Sunnybrook, this flagship weekly lecture series features enlightening talks on key topics related to pursuing medical technology innovation, commercialization and entrepreneurship, aimed at clinicians, engineers and life sciences researchers and trainees.
The Women Founders Fund aims to bridge the gap on entrepreneurial equal opportunity by providing access to resources and empowering growth for female entrepreneurs.
The RBC Post-Doctoral & Graduate Fellowships will support research and innovation at the University of Toronto and recognize emerging leaders who are establishing a record of research, scholarship, and impact, and exhibit the potential to make significant contributions to the body of research in the field of entrepreneurship and innovation.
Founded in 2014, 43North is a startup competition with prizes of $5M USD in investment, dedicated mentorship and free incubator space in Buffalo, NY.
Steadiwear announced that they received FDA registration and that the Steadi-One is now available for pre-order.
RetiSpec was featured in coverage of the Toronto Memory Clinic, where their device to diagnose Alzheimer's disease is currently undergoing clinical trials.
Genome Canada, the Ontario Institute for Cancer Research (OICR) and Thermo Fisher Scientific are collaborating to develop a complete solution of targeted next generation sequencing (NGS) assays and analysis software designed to more effectively assess cancer.
Presented by Falling Walls Lab, participants will pitch their solution to a pressing modern challenge, which is then assessed by an expert jury. One winner is selected to travel to the Lab Finale in Berlin, Germany.
Supported by Ontario Genomics, the Genomic Applications Partnership Program (GAPP) funds downstream research and development projects that address real world opportunities and challenges defined by “Receptor” organizations such as industry, government, or not-for-profit entities.